US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
NL296693A
(fr)
*
|
1962-08-16 |
|
|
|
FR95908E
(fr)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants.
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
DE2902172C2
(de)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins
|
EP0198412B1
(fr)
*
|
1985-04-16 |
1989-03-22 |
F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft |
Dérivés de la phénéthanolamine
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
CN100522159C
(zh)
*
|
2001-01-26 |
2009-08-05 |
先灵公司 |
取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
|
EP1353695A2
(fr)
*
|
2001-01-26 |
2003-10-22 |
Schering Corporation |
Combinaisons d'acide nicotinique et de derives de ce dernier, inhibiteur(s) d'absorption de sterols et traitements de conditions vasculaires
|
RS20100015A
(en)
*
|
2001-01-26 |
2010-12-31 |
Schering Corporation |
Combination of receptor activator activated by fenofibrate peroxisome-proliferator (ppar) with sterol absorption inhibitor ezetimibe for vascular indications
|
ES2296894T3
(es)
*
|
2001-01-26 |
2008-05-01 |
Schering Corporation |
Combinaciones de ezetimiba con aspirina para tratar estados vasculares.
|
DK1385548T3
(da)
*
|
2001-01-26 |
2007-09-10 |
Schering Corp |
Kombinationer af sterolabsorptionsinhibitor(er) med (et eller flere) kardiovaskulære midler til behandling af vaskulære tilstande
|
WO2002058733A2
(fr)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinaisons de chelateur(s) des acides biliaires et d'inhibiteur(s) d'absorption des sterols, et traitements pour troubles vasculaires
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
CA2447884A1
(fr)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Procedes pour traiter la maladie d'alzheimer et/ou pour reguler les niveaux de peptides beta-amyloides chez un sujet
|
MXPA04002572A
(es)
*
|
2001-09-21 |
2004-05-31 |
Schering Corp |
Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
WO2003026643A2
(fr)
*
|
2001-09-21 |
2003-04-03 |
Schering Corporation |
Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
OA12905A
(en)
|
2002-08-19 |
2006-10-13 |
Pfizer Prod Inc |
Combination therapy for hyperproliferative diseases.
|
EP1560579A1
(fr)
*
|
2002-11-06 |
2005-08-10 |
Schering Corporation |
Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
|
EP1606287B1
(fr)
*
|
2003-03-07 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
Composés d'azetidinone substitués, formulations et utilisations de ceux-ci pour traiter l'hypercholestérolémie
|
MXPA05009503A
(es)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
DE602004018617D1
(de)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
JP2007510659A
(ja)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
|
MX2007000979A
(es)
*
|
2004-07-26 |
2007-07-11 |
Cotherix Inc |
Tratamiento de la hipertension pulmonar por iloprost inhalado con una formulacion microparticulada.
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
EP2351569B1
(fr)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil dans des thérapies combinées pour le traitement de l'hypertension artérielle pulmonaire
|
WO2007050783A2
(fr)
|
2005-10-26 |
2007-05-03 |
Asahi Kasei Pharma Corporation |
Fasudil en polytherapies pour traiter l'hypertension arterielle pulmonaire
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
WO2008070496A2
(fr)
|
2006-12-01 |
2008-06-12 |
Bristol-Myers Squibb Company |
Inhibiteurs d'amino cetp étendus
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012037665A1
(fr)
|
2010-09-24 |
2012-03-29 |
Oral Delivery Technology Ltd. |
Oxyde nitrique libérant un ester d'acide aminé pour le traitement de l'hypertension pulmonaire et autres états respiratoires
|
CA2905438A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
RU2618628C1
(ru)
|
2013-04-17 |
2017-05-05 |
Пфайзер Инк. |
Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
|
EP3004138B1
(fr)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
CA3125765A1
(fr)
|
2019-01-18 |
2020-07-23 |
Astrazeneca Ab |
Inhibiteurs de pcsk9 et leurs procedes d'utilisation
|